Comparative study of different glycating agents on human plasma and vascular cells
- 51 Downloads
Diabetic complications are associated with the glycation and formation of advanced glycation end products (AGEs) which leads to structural modifications of biomolecules further affecting cells. Carbonyl compounds such as methylglyoxal and glyceraldehyde-3-phosphate are highly reactive and form an elevated amount of AGEs as compared to glucose and fructose. The investigation of glycation modifications by different compounds may be important to assess the specific pattern of biomolecular and cellular modifications and compare their glycation potential. The present work aims to comprehensively and comparatively examine the effect of glycating agents (glucose, fructose, ribose, methylglyoxal, and glyceraldehyde) on plasma, erythrocytes, platelets, and blood DNA. Glycation of plasma, cells, and DNA was initiated by incubating them with glycating agents for 24–48 h at 37 °C. Negative control samples (without glycating agents) were maintained simultaneously. After treatment, plasma and DNA samples were dialyzed and cell lysate was prepared. Markers of glycation (fructosamine), structural modifications (free amino, β-amyloid, absorption spectra), antioxidant indices (catalase activity, glutathione) and erythrocyte hemolysis were estimated. In the presence of glycating agents, there was a significant increase in the formation of fructosamine, structural modification markers and depletion in antioxidant indices. Overall results suggest that among all glycating agents; methylglyoxal and glyceraldehyde have more potency of glycation induced structural modifications in plasma and vascular cells. This indicates the specific glycation modifications in plasma and vascular cells by various glycating agents may be investigated further for controlling diabetic pathological changes.
KeywordsGlycation Erythrocytes Platelets DNA Plasma
- 8 OHDG
(2,2-Azobis (2-amidinopropane) hydrochloride
Advanced glycation end products
5, 5′-Dithiobis (2-nitrobenzoic acid)
Phosphate buffer saline
Reactive oxygen species
White blood cells
We greatly acknowledge all the participants who volunteered in this study and Bharati Vidyapeeth Hospital for providing samples.
Compliance with ethical standards
Conflict of interest
The author declares that they have no conflict of interest.
- 15.Dutta U, Cohenford MA, Dain JA (2006) Monitoring the effect of glucosamine and glyceraldehyde glycation on the secondary structure of human serum albumin and immunoglobulin G: an analysis based on circular dichroism, thermal melting profiles, and UV–fluorescence spectroscopy. Anal Biochem Acta 558:187–194CrossRefGoogle Scholar
- 18.Adeshara KA, Diwan AG, Jagtap TR, Advani K, Siddiqui A, Tupe RS (2017) The relationship between plasma glycation with membrane modification, oxidative stress and expression of glucose transporter-1 in type 2 diabetes patients with vascular complications. J Diabetes Complic 31(2):439–448CrossRefGoogle Scholar
- 19.Wautier JL, Wautier MP, Schmidt AM, Anderson GM, Hori O, Zoukourian C, Capron L, Chappey O, Yan SD, Brett J et al (1994) Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci USA 91(16):7742–7749PubMedCrossRefPubMedCentralGoogle Scholar
- 28.Sambrook JF, Russell DW (2001) Molecular cloning: a laboratory manual, vol 1–3, 3rd edn. Cold Spring Harbor Laboratory Press, New YorkGoogle Scholar
- 31.Baraka VJ, Navarra G, Leone M, Bourdon E, Militello V (1840) Rondeau P (2014) Deciphering metal-induced oxidative damages on glycated albumin structure and function. Biochim Biophys Acta 6:1712–1724Google Scholar
- 35.Aebi H (1984) Catalase in vitro. In: Packer L (ed) Methods enzymol, vol 105. Academic Press, New York, pp 121–126Google Scholar
- 36.Monnier VM, Genuth S, Sell DR (2016) The pecking order of skin advanced glycation endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in type 1 diabetes. Glycoconj J 33:569–579PubMedPubMedCentralCrossRefGoogle Scholar
- 61.Thornalley PJ (1999) The clinical significance of glycation. Clin Lab 45:263–273Google Scholar